Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probio-Tec BG-VCap-6.5 + magnesium chloride
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probio-Tec BG-VCap-6.5 + magnesium chloride is a combination dietary supplement consisting of a probiotic formulation and the mineral magnesium chloride. The probiotic component, Probio-Tec BG-VCap-6.5, contains two well-characterized strains: *Lactobacillus rhamnosus* (LGG) and *Bifidobacterium animalis* subsp. *lactis* (BB-12). These strains are known for their beneficial effects on gut health, immune modulation, and potential support for mood regulation through the gut-brain axis[1][8]. Magnesium chloride is an essential mineral used to correct or prevent low blood levels of magnesium; it plays key roles in cellular function, nerve transmission, muscle contraction, bone health, and cardiovascular function[2][5]. This combination has been studied as a co-supplementation strategy to reduce inflammation (as measured by C-reactive protein), with some evidence suggesting benefit in individuals with obesity and depressed mood but no significant effect on cognition or intestinal integrity over nine weeks[1]. The product is not classified as a pharmaceutical drug but rather as a dietary supplement.
- Brand names
- Probio-Tec BG-VCap-6.5 + magnesium chloride
02
Targets
ITGB1 (Integrin beta-1)TRPM6
Beyond the preview
Go deeper on Probio-Tec BG-VCap-6.5 + magnesium chloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probio-Tec BG-VCap-6.5 + magnesium chloride.